NEW YORK, Oct. 31, 2014 /PRNewswire/ -- Analyst Brief by Small Cap Traders.  Tenax Therapeutics, Inc. (NASDAQ: TENX) an emerging competitor, is engaged in the business of developing biotechnology products in the nature of blood substitutes with a focus on oxygen delivery to tissue. It is currently developing Oxycyte™, a product which is a safe and effective oxygen carrier for use in surgical and similar medical situations. The Company's Oxycyte oxygen carrier product is a perfluorocarbon emulsified with water and a surfactant, which is provided to the patient intravenously.

Further development of this product has resumed after the lifting of a hold by the FDA.  Prior to the initiation of any human clinical studies using Oxycyte in the US, the company will need to develop an FDA approved protocol which will incorporate FDA input on the design and safety measures to be utilized in such studies. Oxygen has been enrolling patients outside of the US in a Phase II-b study to evaluate the safety and tolerability of Oxycyte in patients with severe non-penetrating traumatic brain injury (STOP-TBI). The study was recently enrolling patients in Israel for the second cohort of a three cohort trial.

The analyst report discusses in more detail the current technical exhaustion setup that is developing.  Technical insights, trading targets, support and resistance are provided that should be of interest to aggressive and tactical traders.

There is no cost obligation required to view analyst brief: 

http://bit.ly/-TENX-AnalystBrief

Copy and paste to browser may be required.

About Small Cap Traders

Once you have read our reports written by financial analysts you will understand that we make every effort to provide informative equity research reports for interested parties.

3rd party financial analysts provide a straightforward assessment of the profiled company and have pledged to remain free of influence when writing research reports. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.

Forward-Looking Disclaimer   

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.   

Compliance Procedure   

Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.

A full disclaimer can be found by viewing the analyst report.

If you wish to have a company covered in more detail by our team, or wish to learn more about our services, please contact us at editor@smallcaptraders.com. For any urgent concerns or inquiries please contact us at editor@smallcaptraders.com.   

Contact: editor@smallcaptraders.com

SOURCE Small Cap Traders